6-7 December 2017

London

Speakers from 2016

Expand/Collapse

Sam Jackson
Programme Manager, National Centre for the Replacement,
Refinement and Reduction of Animals in Research

Day Two

Thursday 8th December, 2016

15.50 | Panel Discussion: Engineering Predictive Tumour Microenvironment Models

Vincent Dubois
Senior Clinical Pharmacokineticist
MedImmune

Workshop A

Tuesday 6th December

10.00 | Fundamental Guide to Leveraging In Silico Models to Improve Predictability and Understand Applications in Cancer Immunotherapy Drug Discoveries

Bruno Gomes
Head of Tumour Immunology
iTeos Therapeutics

Workshop B

Tuesday 6th December

14.00 | Do We Still Need In Vivo Models for the Preclinical Pharmacology Assessment of New IO Drugs?

Day Two

Thursday 8th December, 2016

15.20 | Developing Innovative Immune Cell Co-Culture Models for New IO Drugs Screening and Characterisation

Markus Reschk
Research Laboratory Head
Boehringer-Ingelheim

Day Two

Thursday 8th December, 2016

11.50 | Ex-Vivo Analysis for Understanding Tumour-Infiltrating Immune Cell Composition

Helen Tomkinson
Head of Oncology Quantitative Clinical Pharmacology
AstraZeneca

Day One

Wednesday 7th December, 2016

14.20 | A Quantitative Systems Pharmacology Model of Immuno-Oncology

Anita Seshire
Laboratory Head of Oncology
Merck Biopharma Global R&D

Day Two

Thursday 8th December, 2016

12.30 | Comparison of 2D and 3D Tissue Culture Modelling to Improve Preclinical Validation of Targeted Therapies

Michael Rugaard Jensen
Head of Drug Discovery Pharmacology
Novartis

Day One

Wednesday 7th December, 2016

12.50 | Novel Concept in Preclinical Optimization of Dosing Regimen for HDM201, a Small Molecule HDM2 Inhibitor

Day Two

Thursday 8th December, 2016

09.40 | Large Scale Mouse Model Screening to Improve Drug Response and Resistance in Cancer Patients

Aurelie Courtin
Senior Research Associate, Translational Research
Astex Pharmaceuticals

Day Two

Thursday 8th December, 2016

10.10 | Xenograft Models of Acquired Resistance to TKI and their use in Preclinical Development

Adam Nopora
Group Head of In Vivo Pharmacology
Roche

Day One

Wednesday 7th December, 2016

16.20 | Breakout Roundtable Sessions

Niina Veironmaki
Head of In Vivo Oncology
Alligator Bioscience

Day One

Wednesday 7th December, 2016

11.50 | Of Mice and Not Men: Syngeneic, Transgenic or Humanized Immune-Oncology Mouse Models?

Dik Van Gent
Associate Professor
Erasmus MC

Day Two

Thursday 8th December, 2016

13.30 | Ex Vivo Functional Assays for Homologous Recombination Deficiency in Breast Cancer

Romain Lara
Senior Scientist & Project Manager
Biosceptre International

Day One

Wednesday 7th December, 2016

15.20 | Use of MultimodalTherapeutic Approach to Target nf-P2X7, a Cancer Apecific Marker

Tao You
PK/PD Modelling Lab Head
Boehringer Ingelheim

Workshop A

Tuesday 6th December

10.00 | Fundamental Guide to Leveraging In Silico Models to Improve Predictability and Understand Applications in Cancer Immunotherapy Drug Discoveries

Brian Keogh
Research Leader of Immunology
Opsona Therapeutics

Day One

Wednesday 7th December, 2016

09.40 | Bidirectional Translation- Bench to Bedside and Back Again

Shannon Burke
Scientist, Oncology Research
MedImmune

Day Two

Thursday 8th December, 2016

14.50 | Capturing the Context: Using Tumour Slices to Study the Tumour Microenvironment and Aid Immunotherapy Drug Discovery

15.50 | Panel Discussion: Engineering Predictive Tumour Microenvironment Models

Laure Humbert
Senior Scientist, Preclinical Biology
Immunocore

Workshop B

Tuesday 6th December

14.00 | Do We Still Need In Vivo Models for the Preclinical Pharmacology Assessment of New IO Drugs?

Sophia Karagiannis
Head of Cancer Antibody Discovery & Immunotherapy
Kings College

Day One

Wednesday 7th December, 2016

14.50 | Interrogating Immunologically Relevant Models for Cancer Therapy and Mechanisms of Effector Cell Activation by IgE Class Antibodies: A Case Study

Mustafa Djamgoz
Professor of Cancer Biology
Imperial College London

Day One

Wednesday 7th December, 2016

17.20 | Chair’s Closing Remarks

16.20 | Breakout Roundtable Sessions

09.00 | Chairman’s Opening Remarks

Day Two

Thursday 8th December, 2016

16.20 | Chair’s Closing Remarks

09.00 | Chairman’s Opening Remarks

Eric Raymond
Head of Medical Oncology
Groupe Hospitalier Paris Saint Joseph

Day One

Wednesday 7th December, 2016

10.10 | Bridging the Gap between Preclinical & Translational Data to Clinical Applications

Anne Collins
Senior Research Associate
University of York

Day Two

Thursday 8th December, 2016

10.40 | Patient Derived Xenografts in Prostate Cancer: Advantages, Limitations and Pitfalls

Rajendra Kumari
CSO
Crown Bioscience

Day One

Wednesday 7th December, 2016

09.10 | Tumour Heterogeneity and Combination Strategies with Immunotherapies

Neal Goodwin
VP of Corporate Research Development
Champions Oncology

Day Two

Thursday 8th December, 2016

09.10 | Advanced PDX Tumour Biology Platforms for Drug Advancement

James Keck
Senior Director of In Vivo Pharmacology
The Jackson Laboratory

Day One

Wednesday 7th December, 2016

12.20 | Utilising Mouse Models to Better Understand the Pathways and Mechanisms of Emerging Immune Therapies

Olaf Hardt
Senior Project Manager R&D
Miltenyi Biotec

Day One

Wednesday 7th December, 2016

10.40 | A Complete Workflow for Isolating Pure Tumour Cell Populations from Primary Tissue for Improved Downstream Analyses

Joachim Grevel
Scientific Director
BAST Inc Limited

Day Two

Thursday 8th December, 2016

13.00 | Clinical Oncology, Why Model it When We Can Measure it?

Karen Blyth
Head of Transgenic Models
Beatson Institute for Cancer Research

Day Two

Thursday 8th December, 2016

15.50 | Panel Discussion: Engineering Predictive Tumour Microenvironment Models